These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 6818043

  • 1. Delayed inhibition of dopamine synthesis by gamma-butyrolactone and baclofen: dopamine autoreceptor supersensitivity?
    Argiolas A, Fadda F, Melis MR, Marcou M, Porceddu ML, Gessa GL.
    Eur J Pharmacol; 1982 Nov 05; 85(1):23-7. PubMed ID: 6818043
    [Abstract] [Full Text] [Related]

  • 2. Long-term application of haloperidol: effects on dopamine and acetylcholine receptors.
    Stock G, Kummer P.
    Int Pharmacopsychiatry; 1981 Nov 05; 16(3):144-53. PubMed ID: 6797983
    [Abstract] [Full Text] [Related]

  • 3. (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis.
    Clark D, Hjorth S, Carlsson A.
    Eur J Pharmacol; 1984 Oct 30; 106(1):185-9. PubMed ID: 6099268
    [Abstract] [Full Text] [Related]

  • 4. d-Amphetamine and gamma-butyrolactone alteration of dopamine synthesis in the terminals of nigrostriatal and mesolimbic neurons. Possible role of various autoreceptor sensitivities.
    Demarest KT, Lawson-Wendling KL, Moore KE.
    Biochem Pharmacol; 1983 Feb 15; 32(4):691-7. PubMed ID: 6403019
    [No Abstract] [Full Text] [Related]

  • 5. Supersensitivity of dopamine-autoreceptors. The effect of gammabutyrolactone in long-term haloperidol treated rats.
    Stock G, Steinbrenner J, Kummer P.
    J Neural Transm; 1980 Feb 15; 47(2):145-51. PubMed ID: 7373289
    [Abstract] [Full Text] [Related]

  • 6. Differential action of bromocriptine on nigrostriatal versus mesolimbic dopaminergic neurons.
    Barton AC, Moore KE, Demarest KT.
    J Neural Transm; 1987 Feb 15; 68(1-2):25-39. PubMed ID: 2879883
    [Abstract] [Full Text] [Related]

  • 7. D-1 type of dopamine autoreceptors are not involved in the regulation of dopamine synthesis in the striatum.
    Watanabe H, Suda H, Sekihara S, Nomura Y.
    Jpn J Pharmacol; 1987 Mar 15; 43(3):327-30. PubMed ID: 3495683
    [Abstract] [Full Text] [Related]

  • 8. Presynaptic dopamine receptors: insensitivity to kainic acid and the development of supersensitivity following chronic haloperidol.
    Bannon MJ, Bunney EB, Zigun JR, Skirboll LR, Roth RH.
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Jun 15; 312(2):161-5. PubMed ID: 6772975
    [Abstract] [Full Text] [Related]

  • 9. Comparison of dopamine synthesis regulation in the terminals of nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons.
    Demarest KT, Moore KE.
    J Neural Transm; 1979 Jun 15; 46(4):263-77. PubMed ID: 528998
    [Abstract] [Full Text] [Related]

  • 10. Absence of synthesis-modulating nerve terminal autoreceptors on mesoamygdaloid and other mesolimbic dopamine neuronal populations.
    Kilts CD, Anderson CM, Ely TD, Nishita JK.
    J Neurosci; 1987 Dec 15; 7(12):3961-75. PubMed ID: 3121804
    [Abstract] [Full Text] [Related]

  • 11. The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo.
    van Oene JC, de Vries JB, Horn AS.
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Oct 15; 327(4):304-11. PubMed ID: 6514014
    [Abstract] [Full Text] [Related]

  • 12. Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo.
    Galloway MP, Wolf ME, Roth RH.
    J Pharmacol Exp Ther; 1986 Mar 15; 236(3):689-98. PubMed ID: 3081705
    [Abstract] [Full Text] [Related]

  • 13. Differential actions of dopamine agonists and antagonists on the gamma-butyrolactone-induced in mouse brain dopamine.
    Gianutsos G, Thornburg JE, Moore KE.
    Psychopharmacology (Berl); 1976 Nov 24; 50(3):225-9. PubMed ID: 826966
    [Abstract] [Full Text] [Related]

  • 14. Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in rats.
    Tissari AH, Rossetti ZL, Meloni M, Frau MI, Gessa GL.
    Eur J Pharmacol; 1983 Aug 05; 91(4):463-8. PubMed ID: 6413231
    [Abstract] [Full Text] [Related]

  • 15. Presynaptic inhibition of dopamine synthesis in rat striatum: effects of chronic dopamine depletion and receptor blockade.
    Reches A, Wagner HR, Jackson-Lewis V, Fahn S.
    Brain Res; 1985 Nov 18; 347(2):346-9. PubMed ID: 3933764
    [Abstract] [Full Text] [Related]

  • 16. Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists.
    Meller E, Helmer-Matyjek E, Bohmaker K, Adler CH, Friedhoff AJ, Goldstein M.
    Eur J Pharmacol; 1986 Apr 16; 123(2):311-4. PubMed ID: 3709668
    [Abstract] [Full Text] [Related]

  • 17. Certain dopamine agonists increase dopamine synthesis in the striatum of rat brain.
    Westerink BH, Feenstra MG, Wirix E, Horn AS.
    Eur J Pharmacol; 1984 Jun 01; 101(3-4):235-41. PubMed ID: 6432559
    [Abstract] [Full Text] [Related]

  • 18. The GABAB antagonist, CGP 35348, antagonizes the effects of baclofen, gamma-butyrolactone and HA 966 on rat striatal dopamine synthesis.
    Waldmeier PC.
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Feb 01; 343(2):173-8. PubMed ID: 1648673
    [Abstract] [Full Text] [Related]

  • 19. The effect of LSD and 2-bromo LSD on the striatal DOPA accumulation after decarboxylase inhibition in rats.
    Persson SA.
    Eur J Pharmacol; 1977 May 01; 43(1):73-83. PubMed ID: 16756
    [Abstract] [Full Text] [Related]

  • 20. Acceleration of the biosynthesis of rat striatal dopamine by incubation and by administration of gamma-butyrolactone.
    Dyck LE, Kazakoff CW.
    J Neurosci Res; 1982 May 01; 8(1):57-65. PubMed ID: 7175978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.